Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant for Nasal Polyps with Asthma
NCT03681093Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in nasal polyps (3 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Nasal Polyp Score at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
fevipiprant
03
Conditions
nasal polyps
Beyond the preview
Go deeper on NCT03681093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681093.